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On 8 December 2013 the new Implementing Regulation (IR) (EU) No 503/2013
2 on applications for 
EU market authorisation of genetically modified (GM) food and feed  submitted in the frame of 
Regulation  (EC)  1829/2003
3  became  fully  effective .  Therefore  it  is  now  mandatory  to  submit 
applications concerning GM plants and their derived food and feed products in accordance with  its 
requirements. The new IR is the outcome of a lengthy discussion process between the Member States 
and the European Commission with the aim of incorporating the existing EFSA Guidance for the risk 
assessment of food and feed from GM plants (EFSA Panel on Genetically Modified Organisms (GMO 
Panel), 2011; referred to hereafter as ‘2011 EFSA Food/Feed GD’) into a legal text. The new IR was 
adopted  by  the  European  Commission  after  having  received  a  positive  opinion  of  the  Standing 
Committee on the Food Chain and Animal Health in April 2013.  
The 2011 EFSA Food/Feed Guidance Document (GD), a revision of an earlier document (EFSA, 
2006), provided more specific guidance to applicants, particularly concerning the conduct, design and 
analysis of field trials for compositional, agronomic and phenotypic comparison, which now have 
sufficient statistical power to detect unintended effects if they exist. In particular, it introduced a new 
methodology, bioequivalence, to enable differences between the GMO event and its conventional 
counterpart to be placed into context and assessed for their biological relevance. The solution that 
EFSA identified was to gather field data for the GM, its conventional counterpart and commercial 
reference varieties, collected concurrently within the same trials. This allows the concept of the history 
of safe use of food items on which the comparative analysis is based to be quantified. Bioequivalence 
is adapted from existing practice in the field of medicine (van der Voet et al., 2011). The distinction 
between statistical significance and biological relevance was also recognised by EFSA’s Scientific 
Committee (SC) (2011a).  
Whilst the risk assessment approach and methodology detailed in the EFSA 2011 Food/Feed GD were 
largely maintained in the IR, there were several important elements newly introduced by the Member 
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States and the European Commission. These elements were in part prompted by the views of certain 
Member States and the desire to improve consumer confidence in GM plants (see e.g. Preamble 11 of 
IR (EC) No 503/2013).  
In the following overview the most relevant differences in the risk assessment requirements between 
the EFSA 2011 Food/Feed GD and the new IR are discussed. 
The IR has several requirements related to the molecular characterisation of GM plants with stacked 
events (i.e. two or more GM events are present in a GM plant) that differ from those presented in the 
EFSA 2011 Food/Feed GD. For example, the new IR requests the re-sequencing of DNA inserts and 
their  flanking  regions  in  GM  plants  containing  stacked  events  and  their  comparison  with  the 
nucleotide sequence of the respective single events. 
 
GM  plants containing stacked events (‘stacks’)  are usually  produced  by  conventional  crossing  of 
parental GM plant lines containing one or more single events without the involvement of additional 
genetic  transformations.  As  outlined  in  the  EFSA  2011  Food/Feed  GD,  the  strategy  for  the  risk 
assessment of such stacks relies on a preceding full risk assessment of the single events and then 
focuses on the identification of potential interactions between the respective single events.  
 
The new requirement to re-sequence DNA inserts and their flanking regions in GM stacks is designed 
to ensure the integrity of the insert in the stack. Previously, during the assessment of stacks, the GMO 
Panel has accepted data produced by Southern analysis to ensure insert integrity. Several Member 
States commented that this technique confirms only the macro structure of the inserts but does not 
inform on small changes, e.g. point mutations that may have occurred. However, it has been reported 
that point mutations leading to single-nucleotide polymorphisms (SNPs), as well as other types of 
small  mutations,  are  naturally  occurring  genomic  changes  contributing  to  the  plasticity  of  plant 
genomes (for review see Weber et al., 2012). SNP frequencies in plant genomes are highly variable 
depending on species, genetic diversity of the cultivars assessed, and whether coding or noncoding 
regions are considered (Maughan et al., 2010). A study in maize MON 810, the only GM maize event 
authorised to date for cultivation in the EU, concluded that the mutation rates of the insert and its 
flanking regions were not different from those observed in other maize sequences (La Paz et al., 
2010). Mutations can occur spontaneously in  GM as well as in  non-GM crop plants during their 
growth in the field, but these affect single plants, with a huge dilution effect at harvest, minimising the 
likelihood of any adverse impact on human health or the environment. Since there is no evidence from 
the  scientific  literature  indicating  that  small  sequence  changes  should  be  analysed  for  the  safety 
evaluation of a stacked event, the added value of this new requirement is unclear. 
 
The toxicological assessment of GM plants intended for food/feed production is impacted by a major 
change  in  the  new  IR,  which  now  requires  a  mandatory  90-day  rodent  feeding  study  for  single 
transformation events. 
The toxicological evaluation of GM plants and derived products  as laid down in the EFSA 2011 
Food/Feed GD, in line with Regulation (EC) No 1829/2003, is performed by comparing the GM plant 
with an appropriate non-GM control. It is primarily informed by results from the preceding molecular 
characterization and the comparative compositional, agronomic and phenotypic analysis of the GM 
plant which, on a case-by-case basis, may trigger additional, appropriate toxicological studies, for 
example  on  constituents  newly  expressed  in  the  GM  plant.  Typical  examples  of  case-by-case 
requirements are the 28-day oral toxicity study in rodents on newly expressed protein(s), and the 90-
day study in rodents when driven by a specific hypothesis identified in the preceding evaluation. The 
new IR introduces a significant shift in the approach to the 90-day study in rodents: from a study 
needed on a case-by-case basis to a mandatory requirement. The EFSA Guidance on conducting a 
repeated dose 90-day toxicity study in rodents on whole food/feed (EFSA SC, 2011b) is specifically 
quoted in the IR as the reference guidance document for the study design and statistical approach. 
However,  the  study  is  now  intended  to  fulfil  two  separate  roles:  to  support  the  identification  of 
potential adverse effects in the whole genetically modified food/feed (representing an exploratory Editorial: New Implementing Regulation for GM plant applications 
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study) and to address remaining uncertainties (representing a confirmatory, hypothesis-driven study). 
Given the now mandatory nature of the 90-day study, EFSA is faced with the challenge to determine 
how such an exploratory study should be interpreted within toxicological risk assessment.  
For  allergenicity,  both  the  EFSA  2011  Food/Feed  GD  and  the  IR  follow  the  same  strategy,  
considering the allergenicity of the newly expressed proteins and the endogenous allergenicity of the 
whole GM plant. While allergenicity assessment of the newly expressed protein requires similar data 
sets in both documents, assessment of the endogenous allergenicity of the whole plant contains a 
significant change: building on an EFSA recommendation, the quantitative measurement of known 
plant allergens as part of the compositional analysis is now a mandatory requirement in the IR. 
The whole GM plant is assessed for its endogenous allergenicity in case the recipient plant is known to 
be allergenic. For example in soybean the allergen repertoire of the GM plant has historically been 
compared with that of its non-GM comparator(s), with the use of sera from individuals allergic to 
soybean. This approach has limitations due to the intrinsic variability between allergic individuals and 
the  difficulty  of  obtaining  well-characterised  sera.  Consequently,  the  EFSA  2011  Food/Feed  GD 
recommends that, in order to minimise the use of human sera, relevant known endogenous allergens 
could be included in the comparative compositional analysis, which would imply a quantification of 
the relevant allergens of a crop (see also EFSA GMO Panel, 2010). Several technologies (e.g. mass 
spectrometry),  which  do  not  require  human  sera,  have  proven  useful  in  the  quantification  of 
endogenous allergens (Fernandez et al., 2013). The IR takes this EFSA recommendation forward by 
requesting the mandatory inclusion of endogenous allergens of a crop plant, as referred to in relevant 
OECD (Organisation for Economic Co-operation and Development) documents (e.g. OECD, 2012), 
within the compositional analysis. This is expected to provide robust, quantifiable and reproducible 
information for risk assessment. 
The new elements in the IR have triggered several activities within EFSA. One is an update of the 
EFSA submission guidance (EFSA, 2011) which advises and supports applicants in the preparation 
and presentation of a dossier. This update incorporates the new elements in the IR and has been 
published on the EFSA website
4.  
In addition, EFSA has set up  a  Task Force
5  to provide clarity concerning the objectives of the 
mandatory 90-day rodent feeding study in GM risk assessment and more detailed instructions on how 
to apply the  existing  EFSA Guidance (EFSA SC,  2011b).  The  Task Force,  consisting of  EFSA 
scientists with relevant expertise, aims to deliver a Statement in April 2014 for publication in the 
EFSA Journal. To ensure consistency and scientific quality, external reviewers with relevant expertise 
will be appointed and the relevant EFSA scientific Panels (GMO Panel, NDA Panel and the Scientific 
Committee) will be consulted.  
In summary, whilst the new IR reflects largely the content of the EFSA 2011 Food/Feed GD, several 
important new elements have been added by the Member States and the European Commission. Some 
of the new elements are in line with EFSA recommendations, for example  regarding allergenicity. 
Other elements are a significant modification of the current EFSA requirements, amongst which the 
mandatory requirement for the 90-day rodent feeding study to support the toxicological assessment of 
single transformation events seems the most controversial and challenging.  It should be noted that a 
review of the requirement for a mandatory 90-day study is clearly foreseen by the legislator by 2016. 
The Commission will perform this review based on new scientific information such as the outcome of 
the  EU  seventh  Framework  project  GRACE  (GMO  Risk  Assessment  and  C ommunication  of 
Evidence) (see Art. 12, IR 503/2013). The key research objectives of GRACE
6 include to ‘test various 
types of animal feeding trials [explanation added by authors: including 90-day rodent feeding studies 
with GM plant derived feed], as well as alternative in vitro methods in order to determine how suitable 
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they are and what useful scientific information they provide for health risk assessments of GM food 
and feed’.  
Looking into the mid-term future, the new IR and the EFSA 2011 Food/Feed GD will co-exist, since 
application dossiers compiled in line with the EFSA GD and submitted before 8 December 2013 will 
continue to be assessed under the EFSA GD. Moreover, notwithstanding the coming into force of the 
IR, EFSA will fulfil its ongoing mission to develop new or additional guidance for the risk assessment 
of GM plants, taking into account new scientific developments and methodologies. For example, an 
additional guidance on the agronomic and phenotypic characteristics of a GM plant is currently being 
developed by a dedicated Working Group of the EFSA GMO Panel
7. The IR explicitly foresees future 
reviews incorporating new EFSA guidance (see Art. 12, IR 503/2013). 
The safety and usefulness of GM plants is subject to an intense political and societal  debate, 
characterised by widely diverging positions in different EU Member States.  Considering that the IR 
was endorsed by the Member States with a qualified majority, one expectation is that risk assessment 
requirements outlined in the IR will satisfy the majority of Member States, and allow them to support 
safety conclusions on GM Plants, where appropriate. The future will show whether the IR will  fulfil 
this expectation and contribute to a convergence of Member States views on the safety of GMOs. 
 
 
 
About the Authors 
Elisabeth Waigmann, Head of EFSA GMO Unit since 2012; Ana Gomes, EFSA GMO Unit, Team 
Leader Molecular Characterization; Anna Lanzoni, EFSA GMO Unit, Senior Scientist toxicology; 
Joe N. Perry, Chair of the EFSA Panel on Genetically Modified Organisms from 2012 to 2015. 
 
 
REFERENCES 
EFSA  (European  Food  Safety  Authority),  2006.  Guidance  document  of  the  Scientific  Panel  on 
Genetically  Modified  Organisms  for  the  Risk  Assessment  of  Genetically  Modified  Plants  and 
Derived Food and Feed. The EFSA Journal 2006, 99, 1-100. 
EFSA (European Food Safety Authority), 2011. EFSA guidance on the submission of applications for 
authorisation of genetically modified food and feed and genetically modified plants for food or feed 
uses  under  Regulation  (EC)  No  1829/2003.  EFSA  Journal  2011;9(7):2311,  27  pp. 
doi:10.2903/j.efsa.2011.2311 
EFSA Panel on Genetically Modified Organisms (GMO), 2010. Scientific opinion on the assessment 
of  allergenicity  of  GM  plants  and  microorganisms  and  derived  food  and  feed.  EFSA  Journal 
2010;8(7):1700, 168 pp. doi:10.2903/j.efsa.2010.1700 
EFSA Panel on Genetically Modified Organisms (GMO), 2011. Guidance for risk assessment of food 
and  feed  from  genetically  modified  plants.  EFSA  Journal  2011;9(5):2150,  37  pp. 
doi:10.2903/j.efsa.2011.2150 
EFSA Scientific Committee (SC), 2011a. Statistical Significance and Biological Relevance. EFSA 
Journal 2011;9(9):2372, 17 pp. doi:10.2903/j.efsa.2011.2372 
                                                       
7  http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2013-00606 Editorial: New Implementing Regulation for GM plant applications 
 
EFSA Journal 2013;11(12):e11121  5 
EFSA Scientific Committee (SC), 2011b. EFSA guidance on conducting repeated-dose 90-day oral 
toxicity  study  in  rodents  on  whole  food/feed.  EFSA  Journal  2011;9(12):2438 ,  21  pp. 
doi:10.2903/j.efsa.2011.2438 
Fernandez A, Mills ENC, Lovik M, Spoek A, Germini A, Mikalsen A and Wal JM, 2013. Endogenous 
allergens and compositional analysis in the allergenicity assessment of genetically modified plants. 
Food and Chemical Toxicology, 62, 1-6.  
La Paz JL, Pla M, Papazova N, Puigdomènech P and Vicient CM, 2010. Stability of the MON 810 
transgene in maize. Plant Molecular Biology, 74, 563-571. 
Maughan  PJ,  Yourstone  SM,  Byers  RL,  Smith  SM,  and  Udall  JA,  2010.  Single -Nucleotide 
Polymorphism Genotyping in Mapping Populations via Genomic Reduction and Next-Generation 
Sequencing: Proof of Concept. The Plant Genome, 3, 166-178. 
OECD  (Organisation  for  Economic  Co-operation  and  Development),  2012.  Revised  consensus 
document on compositional considerations for new varieties of soybean [Glycine max (L.) Merr.]: 
key food and feed nutrients, antinutrients, toxicants and allergens. Series on the Safety of Novel 
Foods and Feeds No 25. ENV/JM/MONO(2012)24. 
van der Voet H, Perry JN, Amzal B and Paoletti C, 2011.  A statistical assessment of differences and 
equivalences between genetically modified and reference plant varieties.  BMC Biotechnology, 11, 
15. 
Weber N, Halpin C, Hannah LC, Jez JM, Kough J and Parrott W. 2012. Editor’s choice: crop genome 
plasticity and its relevance to food and feed safety of genetically engineered breeding stacks. Plant 
Physiology, 160, 1842-1853. 
 